TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01804179

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baseline Visit Survey
Description: In both conditions, patients will participate in a Baseline Survey. Three brief items will be used to assess patient-provider discussion and recommendation: (1) Was colorectal cancer or colorectal cancer screening one of the things you discussed with the doctor or health care provider? (Yes/No). (2) If Yes, who brought the topic of colorectal cancer first? (patient/health care provider). (3) Did your doctor or health care provider recommend colorectal cancer screening? (Yes/No). These questions are necessary to evaluate the impact of interventions on patient-provider discussion of CRCS and provider recommendation of CRCS.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Baseline Visit Survey
Description: In both conditions, patients will participate in a Baseline Survey. Three brief items will be used to assess patient-provider discussion and recommendation: (1) Was colorectal cancer or colorectal cancer screening one of the things you discussed with the doctor or health care provider? (Yes/No). (2) If Yes, who brought the topic of colorectal cancer first? (patient/health care provider). (3) Did your doctor or health care provider recommend colorectal cancer screening? (Yes/No). These questions are necessary to evaluate the impact of interventions on patient-provider discussion of CRCS and provider recommendation of CRCS.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up Questionnaire
Description: 12 months after participants began to participate in the study, they will be contacted via telephone to complete a final set of questionnaires. Participants will be asked questions similar to those answered in baseline. This time they will ask about the participant's thoughts on the educational materials as well.
Study: NCT04676581

Intervention type: OTHER
Intervention: Leech Therapy
Description: Patient who received leeches (for more than 2 days) at the Amiens University Hospital over a period of 9 years (2010-2018)

Intervention type: OTHER
Intervention: Leech Therapy
Description: Patient who received leeches (for more than 2 days) at the Amiens University Hospital over a period of 9 years (2010-2018)
Study: NCT01804179

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up Questionnaire
Description: 12 months after participants began to participate in the study, they will be contacted via telephone to complete a final set of questionnaires. Participants will be asked questions similar to those answered in baseline. This time they will ask about the participant's thoughts on the educational materials as well.
Study: NCT01154231

Intervention type: DRUG
Intervention: Nonacog Alfa (Genetical Recombination)
Description: Patients with hemophilia B (congenital blood coagulation factor IX deficiency) who are administered this drug.~Patients with hemophilia B are either patients for whom treatment was already started with a blood coagulation factor IX product (Previously treated patients: hereinafter, PTPs) or patients who have no history of treatment with a blood coagulation factor IX product in the past and for whom treatment will be started with this drug for the first time (Previously untreated patients: hereinafter, PUPs).~The definition of PUPs in this survey is Patients in whom the total number of days of administration of a blood coagulation factor IX product other than this drug before administration of this drug was 3 exposure days (actual number of days of administration: hereinafter, EDs) or less.
Study: NCT04348201

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: foot reflexology
Description: foot reflexology session which takes about 20 minutes. The position of the patient during reflexology session was a relaxed comfortable supine lying position. The therapist was sitting position at the level of the feet. The Session of reflexology was done on three points at both feet.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: dietary modification
Description: diet must be rich in vitamins as fish and beans, calcium as milk and chess, low fat food through decrease oil in meals, high fiber food through all types of vegetables and fruits and restrict caffeine
Study: NCT02711163

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extensively Hydrolyzed formula

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Amino acid formula
Study: NCT03295955

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin Clavulanate
Description: Per-oral Amoxicillin Clavulanate Given or Non-given, after surgery
Study: NCT00524940

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated, Split-Virion Influenza Virus
Description: 0.5 mL, Intramuscular
Study: NCT02109809

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total nodal irradiation
Description: Undergo TLI
Study: NCT01034878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib will be administered orally at a dose of 50 mg once daily, in six weeks cycles consisting of 4 weeks of treatment followed by 2 weeks without treatment.
Study: NCT00631592

Intervention type: DRUG
Group type: OTHER
Intervention: GSK1349572
Study: NCT02109809

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT03799432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COAST-IS
Description: COAST-IS has been designed to equip organizations with the knowledge, motivation, and skill needed to thoughtfully match implementation strategies to identified determinants by applying intervention mapping. The COAST-IS intervention will include four different modes of delivery: 1) dissemination of educational materials; 2) five web-based interactive education sessions on the need for tailoring implementation strategies and the application of intervention mapping; 3) site visits to discuss change objectives necessary to successfully implement trauma-focused cognitive behavioral therapy; and 4) organizational coaching related to using an intervention mapping approach.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TF-CBT Learning Collaborative
Description: The learning collaborative model was adapted from the Breakthrough Series Collaborative model. Leadership of the collaboratives includes experts in evidence-based practices, implementation, and quality improvement. Main components include: 1) three face-to-face learning sessions (2-days each) that provide clinical training; 2) post-learning session action periods structured to facilitate therapists' application of learned skills; 3) a secure website to facilitate faculty-to-participant and peer-to-peer learning and document use of quality improvement methods; 4) fidelity monitoring and coaching; 5) a senior leader track supporting organizational change; 6) monthly outcomes monitoring; and 7) sustainability planning.
Study: NCT00704860

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open label pharmacotherapy
Description: Dosage and drug types change based on patients need and response.~doxepin, clomipramine, amoxapine, amitriptyline, maprotiline, desipramine, nortriptyline, trimipramine, imipramine, protriptyline, isocarboxazid, phenelzine, tranylcypromine, moclobemide, fluvoxamine, paroxetine, fluoxetine, sertraline, citalopram, escitalopram, venlafaxine, atomoxetine, pramipexole, bromocriptine, quetiapine, clozapine, olanzapine, ziprasidone, aripiprazole, paliperidone, Risperidone, bupropion, mirtazapine, pindolol, topiramate, trazodone, Lithium,
Study: NCT02606058

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deferred cord clamping
Description: Deferred cord clamping (for 60 seconds or more with the baby held below or at the level of the placenta)
Study: NCT03691662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-117 Ophthalmic Solution
Description: Topical DE-117 Ophthalmic Solution once daily and Vehicle once daily for 3 months
Study: NCT03799432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TF-CBT Learning Collaborative
Description: The learning collaborative model was adapted from the Breakthrough Series Collaborative model. Leadership of the collaboratives includes experts in evidence-based practices, implementation, and quality improvement. Main components include: 1) three face-to-face learning sessions (2-days each) that provide clinical training; 2) post-learning session action periods structured to facilitate therapists' application of learned skills; 3) a secure website to facilitate faculty-to-participant and peer-to-peer learning and document use of quality improvement methods; 4) fidelity monitoring and coaching; 5) a senior leader track supporting organizational change; 6) monthly outcomes monitoring; and 7) sustainability planning.
Study: NCT03073824

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vSculpt
Description: Pelvic Floor Toning and Vaginal Rejuvenation Device
Study: NCT01508884

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: influenza vaccine
Description: single dose of intradermal 15 mcg non-adjuvanted 2011/2012 trivalent influenza vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: pretreatment with topical imiquimod cream to the injection site before vaccination

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: influenza vaccine
Description: single dose of intradermal 15mcg non-adjuvanted 2011/2012 trivalent influenza vaccine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aqueous cream
Description: pretreatment with topical aqueous cream to the injection site before vaccination

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: influenza vaccine
Description: single dose of intramuscular 15mcg non-adjuvanted 2011/2012 trivalent influenza vaccine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aqueous cream
Description: pretreatment with topical aqueous cream to the injection site before vaccination
Study: NCT04468685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Interperitoneal administration in the gall bladder bed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Interperitoneal administration in the gall bladder bed
Study: NCT03691662

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol Maleate Ophthalmic Solution 0.5%
Description: Topical Timolol Maleate Ophthalmic Solution 0.5% twice daily for 3 months
Study: NCT03338530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive School-Based Intervention
Description: School staff administered the 5 components during the school year. Social Skills Groups were conducted 2-3x/wk. for a total of 60-90 min./wk.; each group contained 3-6 students with social impairments. The Individual Daily Note was administered across the school day to reinforce new skills and reduce problem symptoms. Students' performance on targets was linked to home rewards. Mind Reading computer instruction targeting emotion recognition skills was conducted 3x/wk. for a total of 60 min./wk. Therapeutic Activities were conducted 2x/wk. for a total of 40-60 min./wk.; these cooperative activities were designed to practice targeted skills. Parent Training was conducted 1x/month for 60-90 min./session in order to increase home-school communication and integrate the CSBI across settings.
Study: NCT00491868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R744
Description: 100μg/4week for 8 weeks, then 50\~250μg/4week for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R744
Description: 150μg/4week for 8 weeks, then 50\~250μg/4week for 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rHuEPO
Description: 2250IU or 3000IU(i.v.) 2 or 3 times/week for 8 weeks, then 750\~9000IU(i.v.)/1\~3week for 16 weeks
Study: NCT03416452

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vibratory cueing device
Description: ankle brace with vibrator that provides electric stimulus

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vibratory cueing device
Description: ankle brace with vibrator that provides electric stimulus

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Mobile Gait Trainer
Description: standard rolling walker that has a battery operated sensor attached to the side, designed to detect footsteps

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile Gait Trainer
Description: standard rolling walker that has a battery operated sensor attached to the side, designed to detect footsteps
Study: NCT00491868

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rHuEPO
Description: 4500IU or 6000IU(i.v.) 2 or 3times/week for 8 weeks, then 750\~9000IU(i.v.)/1\~3week for 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R744 placebo
Description: 0 μg/4week for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R744 placebo
Description: 0 μg/4week for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuEPO placebo
Description: 0 IU 2 or 3 times/week for 8 weeks, then 1\~3 times/week for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuEPO placebo
Description: 0 IU 2 or 3 times/week for 8 weeks, then 1\~3 times/week for 16 weeks
Study: NCT02254265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-101 0.05%
Description: OTX-101 0.05% Ophthalmic Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-101 0.09%
Description: OTX-101 0.09% Ophthalmic Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle of OTX-101 Ophthalmic Solution
Study: NCT04553393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide will be added 1 month after responding to CART cells infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine will be added 1 month after responding to CART cells infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide and Decitabine
Description: Both chidamide and decitabine will be added 1 month after responding to CART cells infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine-primed Tandem CAR19/20 engineered T cells
Description: Tandem CAR19/20 engineered T cells
Study: NCT00573352

Intervention type: RADIATION
Group type: OTHER
Intervention: Far Infrared
Description: Far Infrared Radiation (5μm to 20μm wavelength). Duration is 30 to 40 minutes per session
Study: NCT04553393

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Decitabine-primed Tandem CAR19/20 engineered T cells
Description: Tandem CAR19/20 engineered T cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Decitabine-primed Tandem CAR19/20 engineered T cells
Description: Tandem CAR19/20 engineered T cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Decitabine-primed Tandem CAR19/20 engineered T cells
Description: Tandem CAR19/20 engineered T cells
Study: NCT03514095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual Cognitive Stimulation Therapy Program
Description: This program unfolds in 3 weekly sessions of 30 minutes, for 12 weeks, thus completing a total of 36 sessions.~Over the 3 months, the dyad will need to be monitored for orientation / monitoring of intervention by an element of the research team. This monitoring will be bi-weekly, in person or by phone - here according to the choice of the dyad). After each session the caregiver has a questionnaire to complete (intervention monitoring strategy), with the objective of evaluating the acceptability and applicability of the program.
Study: NCT04784611

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Our Peers - Empowerment and Navigational Support (OP-ENS) Peer Health Navigator Intervention
Description: Disability peer health navigator mentored and manualized process of barriers identification, asset mapping, goal setting, and action planning along with on-going social support and information sharing.
Study: NCT00641017

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine
Description: Live attenuated Human Parainfluenza Type 1 Virus Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine
Description: Live attenuated Human Parainfluenza Type 1 Virus Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine
Description: Live attenuated Human Parainfluenza Type 1 Virus Vaccine
Study: NCT00635310

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous liver biopsy
Description: Two passes of PLB from the right hepatic lobe by US guidance (ToshibaTM PLF-308P, Toshiba Co. Ltd., Tokyo, Japan) and 16-gauge automatic cutting needles (Temno EvolutionTM, Allegiance, McGaw Park, IL, USA)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous liver biopsy
Description: Two passes of PLB from the right hepatic lobe by US guidance (ToshibaTM PLF-308P, Toshiba Co. Ltd., Tokyo, Japan) and 16-gauge automatic cutting needles (Temno EvolutionTM, Allegiance, McGaw Park, IL, USA)
Study: NCT00716391

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TPF, radiotherapy and cisplatin.
Description: 3 cycles of: cisplatin: 75 mg/m2, i.v., 1 hour, once daily docetaxel: 75 mg/m2, i.v., 1 hour, once daily 5-fluorouracil: 750 mg/m2, i.v., 24 hours, 5 days Radiotherapy: 70Gy, divided into daily doses of 2 Gray (total days: 35) Cisplatin: 100 mg/m2, i.v., 1 hour, 3 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TPF, radiotherapy and cetuximab.
Description: 3 cycles of: cisplatin: 75 mg/m2, i.v., 1 hour, once daily docetaxel: 75 mg/m2, i.v., 1 hour, once daily 5-fluorouracil: 750 mg/m2, i.v., 24 hours, 5 days Radiotherapy: 70Gy, divided into daily doses of 2 Gray (total days: 35) Cetuximab: 400 mg/m2, i.v, 2 hours, 1 day Cetuximab: 250 mg/m2, i.v, 1 hour, 7 days
Study: NCT01849237

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells
Description: MSCs intravenous infusion of 1-2 millions/kg/day will be performed not more than 10 hs after onset of septic shock in patients with severe neutropenia(≤ 1x10\^9/l).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy of septic shock
Description: Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy of septic shock
Description: Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids
Study: NCT04940988

Intervention type: OTHER
Intervention: Real-time benefits check
Description: Prescribers practicing in outpatient departments assigned to the intervention arm will be shown popup alerts with their patient's insurance benefit design-specific out-of-pocket cost for the drug being ordered as well as out-of-pocket costs for up to 3 lower-cost alternatives if available. Alternatives will only be shown when available and when the patient and his or her benefit design information can be matched by the electronic health record system to accurately query out-of-pocket cost information.
Study: NCT02553772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose Based Eye Drop
Description: Carboxymethylcellulose based eye drop (OM3 Tear) administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboxymethylcellulose Sodium 0.5%
Description: Carboxymethylcellulose sodium 0.5% (REFRESH OPTIVE® ADVANCED) administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.
Study: NCT00623714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Two puffs, of placebo, will be administered to each patient at each prespecified time point. A total of five (5) doses of placebo will be administered during the single blind run-in phase. and matching placebo will be administered in a 3-day period during Periods 1 and 2. Dosing will be twice a day for 3 days, ending after the morning dose on the third day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Two puffs, of placebo, will be administered to each patient at each prespecified time point. A total of five (5) doses of placebo will be administered during the single blind run-in phase. and matching placebo will be administered in a 3-day period during Periods 1 and 2. Dosing will be twice a day for 3 days, ending after the morning dose on the third day.
Study: NCT04667624

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Twynsta
Description: Manufactured by Boehringer Ingelheim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LodineT
Description: •Manufactured by Hanlim Pharm. Co., Ltd, Seoul, Korea
Study: NCT02521415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: intranasal (IN) sub-dissociative ketamine (1mg/kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: Intranasal (IN) fentanyl (1.5 micrograms/kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen or acetaminophen
Description: 10 mg/kg of ibuprofen or 15 mg/kg of acetaminophen will be given to participants prior to the randomized intervention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen or acetaminophen
Description: 10 mg/kg of ibuprofen or 15 mg/kg of acetaminophen will be given to participants prior to the randomized intervention
Study: NCT04222426

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 89Zr-atezolizumab PET scans
Description: Patients receive a total amount of 10 mg unlabeled atezolizumab, this will be added to the tracer to prevent rapid clearance during imaging. A labeled dose of 37 Megabequerell (MBq) 89Zr-atezolizumab (±10%; 1 Millicurie) will then be administered. The tracer will be administered intravenously (i.v.). All patients will undergo two 89Zr-atezolizumab PET scans, one at baseline and one after two doses carboplatin induction treatment. After each tracer injection, 89Zr-atezolizumab PET scans will be performed on day 4 (96 ± 6h after tracer administration).
Study: NCT04019171

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training
Description: 6 weeks of physical exercise training. 3 sessions per week. Session duration : 40 minutes. Self-regulated exercise intensity using Borg's ratings of perceived exertion (RPE)
Study: NCT00462904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI
Description: BPI will be give IV with an initial bolus given over 30 minutes and then a continuous infusion for the next 47.5 hours
Study: NCT00719186

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate
Description: Clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole 2.5 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks